Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 68047-06-3 | Product Number: H1693
(Z)-4-Hydroxytamoxifen
×
![]()
×
Purity: >95.0%(HPLC)
Synonyms:
- (Z)-4-[1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenylbut-1-en-1-yl]phenol
- 4-[(1Z)-1-[4-[2-(Dimethylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]phenol
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 10MG |
$132.00
|
Contact Us | 1 | 26 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | H1693 |
| Purity / Analysis Method | >95.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__6H__2__9NO__2 = 387.52 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (<0°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Hygroscopic,Heat Sensitive |
| CAS RN | 68047-06-3 |
| Reaxys Registry Number | 4910748 |
| MDL Number | MFCD00468090 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 95.0 area% |
| Melting point | 152.0 to 156.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 154 °C |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H302 : Harmful if swallowed. H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. H350 : May cause cancer. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P260 : Do not breathe dusts or mists. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
Related Laws:
| RTECS# | SL1210000 |
Transport Information:
| HS Number | 2922.19.7000 |
Application
(Z)-4-Hydroxytamoxifen: An Active Metabolite of the Estrogen Receptor Modulator (SERM) Tamoxifem
Tamoxifen citrate [T2510] is a widely used non-steroidal antiestrogen agent for the treatment of hormone-dependent breast cancer. Tamoxifen is a prodrug and it is extensively metabolized by cytochrome P450 (CYP450) enzymes to active metabolites including (Z)-4-hydroxytamoxifen and endoxifen (4-hydroxy-N-desmethyltamoxifen). Each acts as an estrogen receptor antagonist in breast tissue. Tamoxifen is commonly referred to as a selective estrogen receptor modulator (SERM) because it acts as an estrogen receptor agonist in other tissues. (The product is for research purpose only.)
References
- Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes
- Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
- Oxidative metabolism of tamoxifen to Z-4-hydroxytamoxifen hydroxytamoxifen by cytochrome P450 isoforms: An appraisal of in vitro studies (a review)
- Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The ‘personalised’ approach?
Application
CRISPR Genome Editing
(Z)-4-Hydroxytamoxifen enhances CRISPR-mediated homology-directed repair (HDR) efficiency.1-4)
References
- Small molecule-triggered Cas9 protein with improved genome-editing specificity
- Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch
- Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing
- HIT-Cas9: A CRISPR/Cas9 Genome-Editing Device under Tight and Effective Drug Control
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.